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Abstract 
Background: Current studies about percutaneous endoscopic gastrostomy (PEG) tube placement report equivalent 
patient outcomes with prophylactic PEG tubes (pPEGs) versus common nutritional support. Unreported was if omit-
ting a pPEG is associated with an increased risk of complications leading to a treatment-related unplanned hospitali-
zation (TRUH).
Methods: TRUHs were retrospectively analyzed in patients with advanced head and neck squamous cell carcinoma 
(n = 310) undergoing (chemo)radiotherapy with (pPEG) or without PEG (nPEG).
Results: In 88 patients (28%), TRUH was reported. One of the leading causes of TRUH in nPEG patients was inade-
quate oral intake (n = 16, 13%), and in pPEG patients, complications after PEG tube insertion (n = 12, 10%). Risk factors 
for TRUH were poor performance status, tobacco use, and surgical procedures.
Conclusions: Omitting pPEG tube placement without increasing the risk of an unplanned hospitalization due to dys-
phagia, dehydration or malnutrition, is an option in patients being carefully monitored. Patients aged > 60 years with 
hypopharyngeal carcinoma, tobacco consumption, and poor performance status appear at risk of PEG tube-related 
complications leading to an unplanned hospitalization.
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Background
Curative intended radiotherapy (RT) with or without 
concomitant chemotherapy of patients with locoregion-
ally advanced (Union for International Cancer Control 
[UICC] 7th edition: stage III–IVB) head and neck squa-
mous cell carcinoma (HNSCC) may lead to malnutri-
tion [1, 2], among other significant toxicities. An already 
existing dysphagia or odynophagia caused by the tumor 
can be aggravated by therapy-related inflammation, 
mucositis, and edema along the mucosal linings of the 
upper aero-digestive tract, as well as in the muscles of 
mastication and swallowing [3–5]. If this leads to grade 
3 dysphagia according to Common Terminology Crite-
ria for Adverse Events (CTCAE version 5.0) [6], feeding 
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tube or total parenteral nutrition and/or hospitalization 
is indicated. Several feeding tube strategies can be used 
for this nutritional support (e.g. nasogastric tube, percu-
taneous endoscopic or percutaneous radiologic gastros-
tomy). Retrospective analyses examining the indication 
for PEG tube placement showed differing results, again 
making a conclusive statement challenging [7]. This is 
further complicated by the fact that a prophylactically 
inserted PEG (pPEG) is sometimes found subsequently 
not to be needed [8]. A comprehensive review found 
weak evidence concerning the pros and cons associated 
with pPEG placement and made a call for more prospec-
tive studies [9, 10]. One of the first prospective studies 
to include enough patients published its first results in 
2012 [10], with an extended follow-up in 2017 [11]. The 
study compared the use of pPEGs with common nutri-
tional support and enteral tube feeding (when considered 
necessary) inserted after the start of treatment reactively 
(rPEG). It resulted in no difference in swallowing func-
tion, tube dependence, and the prevalence of clinically 
relevant esophageal strictures. There was no difference 
in weight, body mass index (BMI), or overall survival 
(OS) between the groups. There was neither an advan-
tage nor a disadvantage for a pPEG versus nPEG or a 
rPEG. However, in this study no complications leading 
to a hospitalization were reported in the nPEG group. 
Our study aimed to analyze if omitting a PEG tube in 
LAHNSCC patients was associated with an increased 
risk of complications leading to an unplanned hospitali-




In this retrospective single-center chart review, we iden-
tified a database of 310 consecutive UICC stage III–IVB 
HNSCC patients (except for nasopharyngeal and sinon-
asal sites) treated between 2007 and 2012 with primary 
or adjuvant chemo-RT with a curative intent. Ethics 
committee approval (Ref.-Nr. KEK-BE: 289/2014) was 
obtained for this study and it has been conducted in full 
accordance with ethical principles, including the World 
Medical Association Declaration of Helsinki (version 
2002) and the additional requirements.
Treatment and follow‑up
Treatment strategies were based on institutional poli-
cies following the case-based multidisciplinary tumor 
board decision, as previously published [12, 13]. Patients 
who were first diagnosed before 2010 (UICC 6th edition) 
were re-staged according to the 7th edition during data 
acquisition. During this period, there was no algorithm 
as to which patient should be recommended for a pPEG. 
Prophylactic PEG placement was recommended to all 
patients based on the subjective evaluation of their gen-
eral condition, expected radiation volume and side effects 
by the attending radiation oncologists. The cases in 
which a patient rejected a pPEG and the reasons of rejec-
tion were not systematically assessed. The planning and 
delivery of RT as well as the definitions of clinical target 
volume and planned target volume followed international 
recommendations [14–18]. The RT was administered 
with 2  Gy daily fractions using a volumetric modulated 
arc technique up to a total dose of 72 Gy for macroscopi-
cally detectable tumor, 66  Gy for postoperative posi-
tive or narrow resection margin(s), and the lymph node 
region(s) with pathological extracapsular extension. Elec-
tive nodal regions received 54 Gy. Sequential boosts were 
performed.
Percutaneous endoscopic gastrostomy placement
Percutaneous endoscopic gastrostomy placements (pPEG 
and rPEG) were performed according to the pull method 
described by Ponsky et  al [19]. Antibiotic prophylaxis 
with Amoxicillin/Clavulanate 1.2  g intravenously and a 
Freka PEG gastral 15 Ch/Fr EnFit (Fresenius Kabi, Swit-
zerland) were routinely used.
Definition of unplanned hospitalizations and follow‑up
All complications leading to a hospitalization from the 
initial histopathological diagnosis to the last follow-up 
were recorded. Emergency or unplanned admissions 
were defined as unplanned hospitalizations (UHs). How-
ever, elective hospitalizations, including those due to 
socially or logistically difficult circumstances (e.g. long 
journey, initially poor general condition, etc.), were not 
analyzed. If an elective hospitalization was associated 
with a complication and therefore an extension to the 
planned length of stay, the time from that complication 
to discharge was defined as an UH. UHs were classified as 
being related to comorbidities, index HNSCC and recur-
rences, or cancer treatment. When a UH was related to 
cancer treatment, it was defined as a treatment-related 
UH (TRUH). In order not to have more than three end-
points and to enable a sound and simple statistical meth-
odology, we analyzed only the first two UHs and thus 
only the first two consecutive TRUHs in patients who 
had multiple UHs. In the case of externally UH, addi-
tional information was obtained from the hospital where 
the emergency took place.
Toxicities and the course of body weight
Toxicities and the course of body weight from the initial 
histopathological diagnosis to the last follow-up were 
recorded and graded according to CTCAE (version 5.0) 
[6]. The patient’s weight was recorded before, during, and 
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after therapy. Changes were graded by CTCAE: grade 
1, 5%–< 10% from baseline, intervention not indicated; 
grade 2, 10–≤ 20% from baseline, nutritional support 
indicated; grade 3 ≥ 20% from baseline, tube feeding, or 
total parenteral nutrition indicated. Symptoms of pain, 
dermatitis, mucositis, dysphagia, xerostomia, and osteo-
radionecrosis were assessed. Acute and late toxicities 
were defined as post-treatment-related complications 
occurring during and/or within 3 months or ≥ 3 months 
after commencing chemo-RT, respectively. Baseline pre-
treatment tumor-related morbidity using the same crite-
ria were also assessed.
Statistical analysis
Patients were grouped as pPEG and nPEG. Patients who 
received rPEG were included in the nPEG group accord-
ing to the intention-to-treat principle. The endpoints 
were defined as: first TRUH (TRUH1), second consecu-
tive TRUH (TRUH2), and overall survival (OS). The 
start date of the first and second TRUH, and the date of 
death, were counted as the corresponding time points, 
respectively. Cox’s proportional hazard model was used 
to evaluate time-to-event endpoints, calculated from the 
date of histopathological diagnosis of the initial HNSCC. 
For multivariate analyses, backwards stepwise elimina-
tion was performed by including variables yielding p val-
ues ≤ 0.05 in univariate analyses. Actuarial time to event 
rates were depicted by Kaplan–Meier methodology. The 
chi-squared test was used to compare categorical vari-
ables. All tests were two-tailed. No adjustment was done 
for multiple testing. Due to the lack of concrete evidence 
or consensus regarding pre-treatment risk factors for 
feeding tube requirement to calculate and assign propen-
sity scores, no matched-pair analyses were performed. 
Statistical analyses were performed with JMP (version 
14.2.0; SAS Institute, Cary, NC, USA).
Results
The median follow-up for the whole patient cohort 
was 32  months (range, 3–99  months). The median fol-
low-up for the nPEG and pPEG group was 35 (range, 
3–94  months), and 32  months (range, 3–99  months), 
respectively. Table 1 shows patient and disease character-
istics. Compared with the nPEG group, the pPEG group 
had more patients aged 70–80  years, with a poor per-
formance status (Eastern Cooperative Oncology Group 
performance status [ECOG PS] 2/3), hypopharyngeal 
tumors, and more advanced T and N stages. The patients 
with pPEG received concomitant chemotherapy more 
frequently and had less frequent grade 2 weight loss dur-
ing therapy than nPEG patients. One hundred forty-one 
of the 310 patients (46%) had at least one UH: 88 (28%) 
were TRUH1, 34 (11%) comorbidity-related, and 19 (6%) 
relapse-related. Sixty-four patients (21%) had two con-
secutive UHs: 34 (11%) were TRUH2, 16 (5%) comor-
bidity-related, and 14 (5%) relapse-related. Table  2 and 
Fig.  1a show an overview of UHs; Table  3 and Fig.  1b 
show an overview of TRUHs.
Beside chemo-RT-related side effects (dermatitis, 
mucositis, infection, pneumonia, and dyspnea), the 
leading causes of TRUH in the nPEG group was dys-
phagia/dehydration/malnutrition. In the pPEG group, 
PEG complications were one of the leading causes for 
TRUH, besides chemo-RT-related side effects (Table  3). 
The comparison of TRUH1 regardless of its cause was 
80% versus 70% (p = 0.09). The comparison of TRUH1 
related to PEG complications or dysphagia/malnutrition/
dehydration related events between nPEG and pPEG 
groups is shown in Fig.  2. There was no significant dif-
ference (p = 0.56). The same analysis was not repeated 
for TRUH2 due to the small number of events (n = 2). 
According to univariate analysis, risk factors for a TRUH 
were: poor ECOG PS (2/3), tobacco use > 40 pack-years 
(i.e. above the median), and surgical procedures ([bilat-
eral] neck dissection, tracheostomy, and pPEG). In mul-
tivariate analysis, tobacco use > 40 pack-years, bilateral 
neck dissection, and poor ECOG PS (2/3) remained as 
independent risk factors for TRUH.(Table 4). We inves-
tigated possible risk factors for a PEG-associated event 
in a subgroup analysis, which revealed that tumor local-
ization to hypopharynx (P = 0.0183), active tobacco 
consumption (P = 0.0009), tobacco use > 40 pack-years 
(P = 0.0001), poor ECOG PS (2/3) (P = 0.0418), and 
age > 60 years (P = 0.0352) were risk factors in the univar-
iate analysis (data not shown). Overall survival at 3 years 
for the entire, nPEG, and pPEG group was 70%, 67%, and 
73%, respectively. Overall survival was associated with 
age, ECOG PS 2–3, tumor localization to the oropharynx 
and hypopharynx, neck dissection, rPEG, and baseline 
BMI (Table 4 and Additional File 1).
Discussion
In a relatively large cohort of 310 patients with locore-
gionally advanced HNSCC compared with previously 
published studies [7, 9, 20–23], we retrospectively ana-
lyzed whether omitting a PEG compared to prophylac-
tic PEG insertion is associated with an increased risk of 
complications leading to a TRUH. Although the institu-
tional policy was to offer pPEG to all patients with locore-
gionally advanced HNSCC, physicians were less keen on 
insisting that patients with a possibly lower risk profile 
should receive a pPEG. Moreover, some patients refused 
the pPEG regardless of their risk profile. Therefore, pPEG 
placement tended to be used more frequently in patients 
with a higher risk profile and worse prognosis (compris-
ing general condition, tumor size, age, hypopharyngeal 
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Table 1 Patient and disease characteristics
Characteristic All patients (n = 310) pPEG
(n = 175)
nPEG or rPEG (n = 135) P value
Age at first diagnosis, years
 Median (range) 61 (20–94) 62 (20–83) 61 (40–94) ns
 ≤ 60, n (%) 139 (44) 75 (43) 64 (47) ns
 > 60– ≤ 70, n (%) 111 (36) 36 (37) 47 (35) ns
 > 70– ≤ 80, n (%) 45 (15) 32 (18) 13 (10) .035
 > 80, n (%) 15 (5) 4 (2) 11 (8) .029
Sex, n (%)
 Female 75 (24) 129 (74) 106 (79) ns
 Male 235 (76) 46 (26) 29 (21) ns
ECOG performance status, n (%)
 0 112 (36) 56 (32) 56 (43) ns
 1 153 (50) 87 (50) 66 (50) ns
 2/3 40 (14) 30 (18) 9 (7) .006
 Missing, n 5 1 4 na
 Median (range) baseline BMI, kg/m2 24.9 (16.8–38.7) 24.9 (16.8–38.6) 24.9 (17.6–36.8) ns
Body weight loss during RT, CTCAE grade, n (%)
 0 135 (47) 92 (55) 43 (36) .002
 1 87(30) 48 (29) 39 (33) ns
 2 62 (22) 26 (15) 36 (30) .004
 3 2 (1) 1 (1) 1 (1) ns
 Missing, n 24 8 16 na
Smoking habits
 Never smoker 34 (13) 21 (13) 13 (12) ns
 Ex-smoker 75 (29) 47 (30) 28 (26) ns
 Current smoker 153 (58) 87 (56) 66 (62) ns
 Missing, n 48 20 28 na
Tobacco use, pack-years
 Median (range) 40 (0–150) 40 (0–150) 40 (0–120) ns
 > 40 (i.e. above median), n (%) 100 (44) 65 (46) 35 (41) ns
 Missing, n 83 34 49 ns
Alcohol abuse, n (%)
 No 85 (33) 54 (35) 31 (31) ns
 In the past 23 (9) 15 (10) 8 (8) ns
 Yes 147 (58) 85 (55) 62 (61) ns
 Missing, n 55 21 34 na
Tumor localization, n (%)
 Oral cavity 63 (20) 36 (21) 27 (20) ns
 Oropharynx 149 (48) 77 (44) 72 (53) ns
 Hypopharynx 44 (14) 33 (19) 11 (8) .008
 Larynx 39 (13) 16 (9) 23 (17) ns
 Multi-compartemental 15 (5) 13 (7) 2 (2) .016
Tumor category, n (%)
 T1 25 (8) 9 (5) 16 (12) .036
 T2 95 (31) 42 (24) 53 (39) .004
 T3 102 (33) 59 (34) 43 (32) ns
 T4 88 (28) 65 (37) 23 (17) < .001
Nodal category, n (%)
 N0 36 (12) 17 (10) 19 (14) ns
 N1 55 (18) 21 (12) 34 (25) .004
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tumor localization; Table  1). In the nPEG group, apart 
from (chemo)-RT-related side effects, dysphagia/dehy-
dration/malnutrition (n = 8; 20%) was the most frequent 
cause of TRUH, whereas in the pPEG group, apart from 
(chemo)-RT-related side effects, PEG-related complica-
tions frequently led to TRUH (n = 11; 14%). There was 
no difference in TRUH caused by PEG complications or 
dysphagia/malnutrition/dehydration after pPEG versus 
nPEG (p = 0.56). PEG tube placement is associated with 
the risk of complications; however, there is a great deal 
of variability in the reported incidence of such compli-
cations [11, 20, 24–29]. The difference in the incidences 
of complications is partly due to the various definitions 
and populations analyzed. For example, complications 
are more likely to occur in older patients with comor-
bidities, especially those with an infection or history of 
aspiration [30]. Compared with the publication of Silan-
der et  al. [10], our rate of PEG-related complications is 
relatively high (14% vs 1%); however, it is relatively low 
compared with a prospective study reporting complica-
tion rates at 2 weeks and 2 months (39% and 27%, respec-
tively) [24]. We hypothesize that our pPEG cohort is a 
different, more fragile patient population that tends to 
have more complications compared with that studied by 
Silander et  al. [10] and our nPEG population. Further-
more, we suspect that patients—like those studied by our 
Swedish colleagues [10]—who are willing to be included 
and randomized in a study, are more compliant than the 
patients with HNSCC seen in our everyday practice, over 
two-thirds of whom have a positive history of alcohol 
abuse and more than 87% a positive history of tobacco 
use [31]. Patients with severe clinical and psychosocial 
impairment and fewer economic resources are more 
BMI body mass index, CTCAE Common Terminology Criteria for Adverse Events, na not applicable, ns not significant, nPEG no PEG, PEG percutaneous endoscopic 
gastrostomy, pPEG prophylactic PEG, rPEG reactive PEG, RT radiotherapy, UICC Union for International Cancer Control
Table 1 (continued)
Characteristic All patients (n = 310) pPEG
(n = 175)
nPEG or rPEG (n = 135) P value
 N2 206 (66) 128 (73) 77 (57) .003
 N3 11 (4) 9 (5) 5 (4) ns
UICC stage (7th edition), n (%)
 III 65 (21) 22 (13) 43 (32) < .001
 IVA 228 (74) 142 (81) 86 (64) < .001
 IVB 17 (5) 11 (6) 6 (4) ns
Surgical interventions, n (%)
 Primary oncologic resection 78 (25) 42 (27) 36 (27) ns
 Neck dissection 214 (69) 121 (69) 93 (69) ns
PEG tube placement, n (%)
 Prophylactic 175 (56) 175 (100) 0 (0) na
 Reactive 34 (11) 0 (0) 34 (25) na
 None 101 (33) 0 (0) 101 (75) na
Median (range) duration of PEG dependency, days 266 (4–2969) 274 (40–2969) 231 (4–2554) < .001
Chemotherapy, n (%)
 Concomitant 266 (86) 161 (92) 105 (78) < .001
 Neoadjuvant 33 (11) 21 (12) 12 (9) ns
Table 2 Overview of unplanned hospitalizations (n = 310)
CX chemotherapy, TRUH treatment-related unplanned hospitalization, UH 
unplanned hospitalization, UH1 first UH event, UH second UH event
UH No. of patients 
(%)
All UHs, no. of events (%)
UH1 UH2
Any UH 141 (45) 64 (21) 205 events in 169 patients
Reason for UH
 Comorbidity-related 34 (11) 16 (5) 50 (24)
  Alcoholism 4 (12) 0 (0) 4 (8)
  Cardiopulmonary 9 (27) 3 (19) 12 (24)
  Gastrointestinal 4 (12) 0 (0) 4 (8)
  Infection 12 (35) 5 (31) 17 (34)
  Other 5 (14) 8 (50) 13 (26)
 Related to tumor or 
relapse
19 (6) 14 (4) 33 (16)
 Treatment-related 
(TRUH)
88 (28) 34 (11) 122 (60)
  Due to PEG 11 (13) 1 (2) 12 (10)
  Due to surgery 3 (3) 1 (3) 4 (3)
  Due to neoadjuvant 
CX
4 (4) 2 (6) 6 (5)
  Due to radio-CX 70 (80) 29 (85) 99 (81)
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Fig. 1 Overview of a causes leading to unplanned hospitalizations (UHs) and b to treatment related unplanned hospitalizations (TRUHs)
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likely to experience treatment compliance problems [31]. 
There is an increasing incidence of oropharyngeal can-
cer, especially in younger patients, and a decrease in the 
previously known risk factors for HNSCC of smoking 
and alcohol use [32, 33]. Previously, typical patients with 
HNSCC tended to be heavy drinkers or smokers; how-
ever, human papillomavirus (HPV)-associated HNSCC 
in younger, fitter, and possibly more compliant patients 
increasingly represent the majority of at least oropharyn-
geal disease [34]. This interesting aspect should be kept 
in mind before considering that in our entire cohort, up 
to one-fifth of patients had a TRUH besides the (chemo)-
RT-induced TRUH—due to dysphagia/dehydration/
malnutrition (20%) in the nPEG group or postopera-
tively after PEG insertion (12%) in the pPEG group. The 
physician and patient have to face the additional risks 
associated with an invasive procedure, such as PEG tube 
placement, or those arising from not performing a sup-
portive surgical procedure to allow sufficient oral intake, 
such as dysphagia/dehydration/malnutrition.
Further differences between our cohort and the Swed-
ish study [10, 11] can be seen with regard to weight loss, 
BMI, and OS between the pPEG and nPEG groups. The 
increased weight loss and BMI differences during RT in 
the nPEG versus pPEG groups could be explained not 
only by the greater compliance of patients but also by the 
prospective setting—and therefore thorough monitoring 
by nutrition counselors in the nPEG cohort—of the Silan-
der et  al. trial [10]. Nutrition counselors were not sys-
tematically involved in the treatment of our patients, and 
some patients categorically refused nutrition counseling. 
The higher risk profile in the pPEG group more easily 
explains the OS difference versus the nPEG group (tumor 
size, age, tumor localization; Table  1), as OS is known 
Table 3 Details of TRUHs (n = 310)
na not applicable, ns not significant, TRUH treatment-related unplanned hospitalization, TRUH1 first TRUH event, TRUH2 second TRUH event, nPEG no percutaneous 
endoscopic gastrostomy, pPEG prophylactic percutaneous endoscopic gastrostomy, rPEG reactive percutaneous endoscopic gastrostomy






No (%) No (%) No (%)
TRUH1 (n = 88)
 Dermatitis/mucositis/oral infection 18 (20) 13 (23) 5 (16)
 Dysphagia/dehydration/malnutrition 15 (17) 7 (12) 8 (26)
 General condition 8 (9) 5 (9) 3 (10)
 Osteonecrosis/dental caries 8 (9) 5 (9) 3 (10)
 Other 11 (11) 7 (13) 4 (13)
 Percutaneous endoscopic gastrostomy 11 (14) 9 (16) 2 (6)
 Pneumonia/dyspnea 17 (19) 11 (19) 6 (19)
 Total 88 (28) 57 (33) 31 (23)
TRUH2 (n = 34)
 Dermatitis/mucositis/oral infection 3 (9) 3 (13) 0 (0)
 Dysphagia/dehydration/malnutrition 1 (3) 1 (4) 0 (0)
 General condition 4 (12) 2 (8) 2 (20)
 Osteonecrosis/dental caries 6 (18) 3 (13) 3 (30)
 Percutaneous endoscopic gastrostomy 3 (9) 0 (0) 1 (10)
 Pneumonia/dyspnea 14 (41) 11 (46) 3 (30)
 Other 3 (9) 4 (17) 1 (10)
 Total 34 (11) 24 (14) 10 (7)
All TRUHs (n = 122)
 Dermatitis/mucositis/oral infection 21 (17) 16 (20) 5 (12)
 Dysphagia/dehydration/malnutrition 16 (13) 8 (10) 8 (20)
 General condition 12 (10) 7 (9) 5 (12)
 Osteonecrosis/dental caries 14 (11) 8 (10) 6 (15)
 Percutaneous endoscopic gastrostomy 12 (12) 11 (14) 1 (10)
 Pneumonia/dyspnea 31 (25) 22 (27) 9 (22)
 Other 13 (11) 9 (11) 4 (10)
 Total number 122 (–) 81 (–) 41 (–)
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to be worse in patients with larger primary tumors and 
hypopharyngeal tumor [35–38]. Other limitations of our 
study, apart from the different risk profiles of the nPEG 
and pPEG groups, include its retrospective nature, the 
lack of stratification according to HPV status, and the 
presence of some patients treated with surgery before RT.
With future changes in the HNSCC population, ther-
apy regimens, and side-effect profile according to the 
HPV status, further analyses of the indication for a PEG 
is necessary [39].
Conclusions
Our retrospective analysis shows that omitting a prophy-
lactic PEG does not lead to more unplanned hospitaliza-
tions compared to patients receiving a PEG tube before 
start of chemoradiation. Patients with a hypopharyngeal 
carcinoma, active tobacco consumption, more than 40 
pack-years of smoking history, and poor ECOG PS seem 
to be at risk of PEG tube-related UH. Prospective trials 
about pPEG, especially for oropharyngeal carcinoma 
Fig. 2 Kaplan–Meier curve comparing treatment-related unplanned hospitalizations (TRUHs) caused by prophylactic PEG tube installment (pPEG) 
versus TRUHs caused by omitting a PEG tube (dysphagia/dehydration/malnutrition)
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Table 4 Univariate and multivariate analysis (Cox proportional-hazard)
Variable TRUH1 TRUH2 OS
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Univariate
 Age, years
  ≤ 60 0.76 (0.48–1.18) .21 0.74 (0.35–1.56) .42 0.63 (0.42–0.96) .0288
  > 60–≤ 70 1.00 (0.64–1.58) .99 1.07 (0.51–2.67) .86 0.92 (0.60–1.40) .6884
  > 70–≤ 80 1.43 (0.82–2.50) .20 1.59 (0.65–3.91) .30 1.40 (0.84–2.34) .1937
  > 80 1.52 (0.61–3.75) .35 0.80 (0.11–5.85) .82 4.25 (2.26–7.99) .0001
 ECOG PS at first consultation, (vs other PS)
  0 0.95 (0.60–1.51) .83 0.89 (0.41–1.91) .76 0.64 (0.41–1.00) .0475
  1 (vs others) 0.73 (0.47–1.14) .16 0.59 (0.28–1.26) .17 1.05 (0.71–1.58) .7939
  2/3 (vs others) 1.99 (1.15–3.45) .01 2.77 (1.23–6.27) .01 2.01 (1.21–3.37) .0061
 Alcohol abuse
  Active 1.16 (0.71–1.88) .55 0.81 (0.36–1.83) .60 1.23 (0.78–1.94) .3783
  Active or in past 1.59 (0.92–2.75) .09 1.17 (0.48–2.85) .72 1.33 (0.82–2.16) .2475
  > 2 units a day (= median) 1.44 (0.81–2.57) .21 0.84 (0.30–2.35) .73 1.06 (0.63–1.79) .8203
 Smoking habits
  Current smoker 1.13 (0.70–1.82) .61 0.94 (0.41–2.13) .87 1.06 (0.68–1.66) .7832
  Current or ex-smoker 1.68 (0.74–3.92) .20 3.39 (0.46–25.1) .20 1.14 (0.59–2.21) .7022
  > 40 pack-years (= median) 1.94 (1.17–3.20) .01 1.98 (0.81–4.85) .12 1.01 (0.63–1.63) .9615
 Tumor localization, yes (vs no)
  Oral cavity 1.06 (0.62–1.81) .83 0.81 (0.31–2.12) .67 0.80 (0.48–1.36) .409
  Oropharynx 0.75 (0.48–1.17) .19 0.75 (0.36–1.56) .43 0.63 (0.42–0.95) .026
  Hypopharynx 1.43 (0.81–2.50) .20 2.00 (0.86–4.69) .10 1.81 (1.11–2.93) .0149
  Larynx 1.21 (0.66–2.23) .53 0.79 (0.24–2.60) .69 1.39 (0.81–2.38) .2251
  Mixed 0.80 (0.25–2.52) .69 1.60 (0.38–6.73) .56 1.81 (0.74–4.48) .1878
 Surgery, yes (vs no)
  Primary oncologic surgery 0.72 (0.42–1.24) .22 0.47 (0.16–1.34) .15 0.79 (0.49–1.29) .3395
  Neck dissection 0.69 (0.44–1.07) .09 0.47 (0.23–0.96) .03 0.66 (0.44–0.99) .0438
  Bilateral ND 1.69 (1.08–2.64) .00 1.75 (0.84–3.67) .13 0.92 (0.58–1.45) .7161
  Tracheostomy 1.78 (1.15–2.77) .01 2.58 (1.24–5.35) .01 1.49 (0.98–2.25) .0594
  pPEG 1.46 (0.93–2.30) .09 2.56 (1.09–5.99) .02 1.24 (0.82–1.86) .3003
  rPEG 2.54 (1.48–4.33) .00 1.75 (0.67–4.58) .25 2.07 (1.25–3.43) .0038
 Chemotherapy, yes (vs no)
  Neoadjuvant 1.53 (0.83–2.83) .57 2.82 (1.20–6.60) .01 1.26 (0.69–2.31) .4535
  Concomitant 1.22 (0.61–2.43) .16 2.08 (0.50–8.76) .30 0.59 (0.35–1.02) .054
 Baseline BMI, kg/m2
  ≤ 18.5 1.11 (0.27–4.54) .89 1.46 (0.20–10.8) .71 3.42 (1.23–9.50) .0115
  > 18.5–< 25 0.70 (0.41–1.22) .20 0.73 (0.30–1.73) .46 0.94 (0.56–1.58) .8135
  ≥ 25 1.39 (0.81–2.38) .22 1.29 (0.55–3.02) .55 0.88 (0.53–1.47) .6231
Multivariate
 Model 1 for TRUH1
  ECOG 2/3 1.73 (0.93–3.23) .10 – – – –
  > 40 pack-years 1.94 (1.17–3.20) .01 – – – –
  Bilateral ND 1.69 (1.02–2.78) .04 – – – –
Model 2 for TRUH2
  ECOG 2/3 – – 2.77 (1.23–6.27) .03 – –
  pPEG – – 2.06 (0.87–4.91) .09 – –
  Neoadjuvant CX – – 3.27 (1.38–7.74) .02 – –
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and its future results concerning de-escalation, are 
warranted.
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